Precision BioSciences Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Precision BioSciences's revenue and earnings are forecast to decline at 13% and 24.9% per annum respectively while EPS is expected to grow by 5.2% per annum.
Wichtige Informationen
-24.9%
Wachstumsrate der Gewinne
5.2%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 24.5% |
| Wachstumsrate der Einnahmen | -13.0% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 20 May 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts
Aug 06
It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks
Jun 23Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?
Mar 14Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?
Dec 08Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles
Sep 02Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash
Aug 16Precision BioSciences Q2 2022 Earnings Preview
Aug 05Precision Bio: Another CAR-T Laggard With No Solid Prospects
May 09Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt
Apr 19Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)
Mar 21Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely
Dec 31Precision BioSciences: Uniquely Positioned
Oct 07Is Precision BioSciences (NASDAQ:DTIL) A Risky Investment?
Sep 24Precision BioSciences: The Right Profile To Progress
Aug 27Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 20 | -75 | -47 | -24 | 6 |
| 12/31/2025 | 18 | -65 | -51 | -55 | 7 |
| 12/31/2024 | 32 | -34 | -76 | -71 | 7 |
| 3/31/2024 | 58 | -20 | -73 | -72 | N/A |
| 12/31/2023 | 49 | -43 | -86 | -84 | N/A |
| 9/30/2023 | 52 | -57 | -100 | -98 | N/A |
| 6/30/2023 | 47 | -40 | -49 | -45 | N/A |
| 3/31/2023 | 31 | -59 | -52 | -48 | N/A |
| 12/31/2022 | 25 | -73 | -49 | -46 | N/A |
| 9/30/2022 | 21 | -76 | -52 | -48 | N/A |
| 6/30/2022 | 38 | -93 | -105 | -101 | N/A |
| 3/31/2022 | 102 | -40 | -113 | -108 | N/A |
| 12/31/2021 | 116 | -31 | -17 | -11 | N/A |
| 9/30/2021 | 118 | -32 | -6 | -1 | N/A |
| 6/30/2021 | 101 | -47 | -4 | 1 | N/A |
| 3/31/2021 | 34 | -101 | 2 | 7 | N/A |
| 12/31/2020 | 24 | -109 | -92 | -87 | N/A |
| 9/30/2020 | 22 | -106 | -104 | -94 | N/A |
| 6/30/2020 | 19 | -101 | -101 | -86 | N/A |
| 3/31/2020 | 24 | -88 | -98 | -77 | N/A |
| 12/31/2019 | 22 | -93 | -96 | -71 | N/A |
| 9/30/2019 | 21 | -87 | -92 | -63 | N/A |
| 6/30/2019 | 18 | -76 | -92 | -64 | N/A |
| 3/31/2019 | 15 | -69 | -77 | -57 | N/A |
| 12/31/2018 | 11 | -46 | -67 | -52 | N/A |
| 9/30/2018 | 7 | -38 | -53 | -46 | N/A |
| 12/31/2017 | 6 | -21 | N/A | -24 | N/A |
| 12/31/2016 | 7 | -8 | N/A | 92 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: DTIL is forecast to remain unprofitable over the next 3 years.
Ertrag vs. Markt: DTIL is forecast to remain unprofitable over the next 3 years.
Hohe Wachstumserträge: DTIL is forecast to remain unprofitable over the next 3 years.
Einnahmen vs. Markt: DTIL's revenue is expected to decline over the next 3 years (-13% per year).
Hohe Wachstumseinnahmen: DTIL's revenue is forecast to decline over the next 3 years (-13% per year).
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if DTIL's Return on Equity is forecast to be high in 3 years time